52-kD SS-A/Ro: Genomic Structure and Identification of an Alternatively Spliced Transcript Encoding a Novel Leucine Zipper-minus Autoantigen Expressed in Fetal and Adult Heart

By Edward K. L. Chan,* Francis Di Donato,‡ John C. Hamel,* Chung-E Tseng,‡ and Jill P. Buyon‡

From the *W. M. Keck Autoimmune Disease Center and DNA Core Laboratory for Structural Analysis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037; and the ‡Department of Medicine, Division of Rheumatology, New York University School of Medicine and the Department of Rheumatic Diseases and Molecular Medicine, Hospital for Joint Diseases, New York 10003

Summary
The 52-kD SS-A/Ro protein is one of the antigenic targets strongly associated with the autoimmune response in mothers whose children have manifestations of neonatal lupus. In addition to the cDNA clone we previously reported for the full-length 52-kD SS-A/Ro protein, an interesting MOLT-4 cDNA clone, p52-2, was found to have an internal deletion of 231 nucleotides including the domain encoding the leucine zipper motif. To further investigate the nature of this deletion, genomic DNA clones were isolated from a AFIXII library. The complete gene for the full-length 52-kD protein (α form, 52α) spans 10 kb of DNA and is composed of seven exons. Exon 1 contains only the 5' untranslated sequence, while the translation initiation codon is located 3 kb downstream in exon 2, which also encodes the three zinc finger motifs. Exon 4 encodes amino acids 168–245, including the coiled coil/leucine zipper domain. Exon 7 is the longest and encodes the rfp-like domain and the 3' untranslated region. The cDNA p52-2 can now be accounted for as a product of alternative messenger RNA (mRNA) derived from the splicing of exon 3 to exon 5, skipping exon 4, which results in a smaller protein (52β) with a predicted molecular weight of 45,000. An initial approach to identifying this alternatively spliced form in the human heart used a ribonuclease protection assay. Using an RNA probe corresponding to bases 674–964 of the full-length cDNA, two protected mRNA fragments were identified, a 290-bp fragment corresponding to expression of 52α and a smaller fragment of 144 bp, the predicted size of 52β. Using reverse transcription followed by polymerase chain reaction, cDNAs from a 16-wk fetal heart, 24-wk heart, and adult heart were amplified with primers flanking exon 4. Two polymerase chain reaction products were observed in each tissue, one 1.0 kb likely representing 52α and a second 0.78 kb, consistent with 52β. The 0.78-kb fragment identified in the 16-wk heart was cloned, and DNA sequencing confirmed the 52β type. Immunoprecipitation of in vitro-translated 35S-labeled 52β form was performed to evaluate the antigenicity of this novel form of 52-kD SS-A/Ro. 26 (87%) of 30 sera tested from mothers whose children were known to have neonatal lupus immunoprecipitated the 52β form. In summary, we herein describe an alternatively spliced mRNA encoding a novel 52 SS-A/Ro autoantigen expressed in a variety of tissues including the fetal heart. Recognition of this 52β isofrom suggests that antigenicity of the 52-kD SS-A/Ro protein can be independent of the putative leucine zipper domain. These findings may further elucidate the cellular function of the 52-kD SS-A/Ro antigen and its role in the development of an autoimmune disease and subsequent injury to fetal tissue.

In addition to the 60-kD SS-A/Ro and 48-kD SS-B/La proteins, another major antigenic target that characterizes the autoimmune response in mothers whose children have manifestations of neonatal lupus is the 52-kD SS-A/Ro protein (1–4). A molecular definition and sequence motifs for this nuclear autoantigen have been provided by the isolation of cDNA clones encoding the full-length protein, which consists of 475 amino acids (5, 6). The deduced
structure contains three distinct domains. The NH2-terminal region is rich in cysteine/histidine motifs known as zinc fingers and belongs to the RING finger protein subfamily, which includes the founding members rfp (7) and rpt-1 (8), and the newly described breast cancer susceptibility gene, BRCA1 (9). The central region contains two putative coiled coils with heptad periodicity, one of which was previously identified to be a leucine zipper. The COOH-terminal domain is similar to the corresponding domain in the rfp protein. The human 52-kD SS-A/Ro gene is located on chromosome 11 (10). Based on its homology with other closely related proteins that function in transcriptional regulation such as rpt-1, it is reasonable to speculate that the 52-kD protein has a similar role. However, the cellular function for the 52-kD SS-A/Ro is not presently defined.

Alternatively spliced messenger RNAs (mRNA)1 have been described for transcription factors as well as inflammatory mediators, signal transduction components, proteins involved in the immune response, growth factor receptors, and other housekeeping proteins. It has been speculated that such mRNAs either suppress the translation of the functional counterpart or represent intermediates that can be further processed depending on the tissue (11). There is accumulating evidence for alternatively spliced forms of the nuclear autoantigens of the SS-A/Ro and SS-B/La systems. Most recently, Troster et al. described an alternative type of SS-B/La mRNA in which an alternative exon 1 (exon 1') was used (12). It was proposed that a second promoter in the previously described intron 1 regulates the transcription of exon 1'. Moreover, albeit secondary to a different splicing event than that described for SS-B/La, two versions of the 60-kD SS-A/Ro protein that diverge in their respective COOH termini have been reported (13, 14).

Insights into understanding the cellular function of the 52-kD SS-A/Ro protein, its antigenicity, and to-date unexplained involvement in the development of fetal cardiac conduction disturbances may be gained as more information on the genomic structure becomes available and potential alternatively spliced mRNAs are identified. Specifically, with regard to the pathogenesis of congenital heart block (CHB), we hypothesized the existence of an isoform in which additional or deleted sequences promote access to autoantibodies or which in turn may function to down-regulate or up-regulate expression of the putative 52-kD SS-A/Ro. Alternative splicing as a means to regulate on-off type gene expression has been described in several sex determining proteins in Drosophila (15). Accordingly, we herein define the genomic structure of the 52-kD SS-A/Ro protein and report the isolation of a novel alternative form in which exon 4 encoding the leucine zipper domain is deleted. With respect to the potential role of this novel anti-

Materials and Methods

MOLT-4 Cell cDNA Library Screening. In our original report (5), after obtaining a partial cDNA for the 52-kD SS-A/Ro from a HepG2 cell cDNA library using an autoantibody, a 5' probe was generated and used to screen a MOLT-4 cell cDNA library. Two specific clones, p52FL and p52-2, were selected for further analysis. The longer cDNA (p52FL) was characterized completely and found to encode the full-length protein (5), while the shorter cDNA (p52-2) was not examined in detail. This study describes the complete sequence analysis of clone p52-2. All nucleotide positions refer to accession number M35041 unless otherwise stated (5).

Genomic DNA Clones of 52-kD SS-A/Ro. The full-length cDNA insert from clone p52FL (5) was labeled by the method of Feinberg and Vogelstein (16) and used for DNA hybridization screening of a human placental genomic DNA library cloned in the AFIIX Vector (Stratagene, La Jolla, CA). Positive clones were plaque purified and examined by restriction enzyme analysis and Southern blotting. Restriction fragments containing the region of interest were identified and subcloned in pBluescript SK (Stratagene).

Mapping of Transcriptional Start Sites. The method of Hielement et al. (17) using 5' rapid amplification of cDNA ends (RACE) to determine the 5'-cap-G structure of mRNA was used. Human placenta 5' RACE-Ready cDNA was purchased from CLONTECH (Palo Alto, CA), and the RACE procedure was performed according to the manufacturer's instructions. The primer 5'-TCAAGGTGTCTGCTGGAACATTTGTAAGT-3' (complementary to nucleotide 78-107) was used in the first PCR together with the provided anchor primer. 10% of the PCR product from the first reaction was used to set up the second PCR with a nested primer 5'-TTAAGGGTTTGGCTTTACAGGGCAACCT-3' (complementary to nucleotide 21-50) used to substitute for the first primer. The second PCR product was analyzed by electrophoresis in a 4% agarose gel and subcloned using a cloning kit (pPCR-Script, Stratagene), and nucleotide sequences were determined from 12 subclones.

DNA Sequence Analysis. Nucleotide sequences were determined using the dye terminator cycle sequencing and a DNA sequencer (373A; Applied Biosystems Inc., Foster City, CA). Oligonucleotide primers were synthesized with a DNA synthesizer (394; Applied Biosystems Inc.). DNA sequences were determined in both strands and compiled using an alignment program (SeqEd; Applied Biosystems Inc.).

RNA Isolation. Human fetal tissues were obtained after elective termination of normal pregnancy by dilatation and evacuation. This was done in accordance with the guidelines of the Institutional Review Board and after obtaining consent from the mothers. RNA was extracted as described (18) using the RNA isolation kit (Stratagene), and adult heart RNA was obtained commercially (CLONTECH).

RNase Protection Assays. Plasmid p52PB containing the internal PstI-BamHI (covering bases 674-964) was constructed to generate an antisense RNA probe. The PstI-BamHI fragment was obtained by a partial PstI and BamHI digestion of full-length RNA from clone p52FL.
52-kD SS-A/Ro cDNA and subcloned into BamHI and PstI sites of pBluescript SK vector. RNase protection assays were carried out using a kit from Ambion Inc. (RPA II; Austin, TX) according to the manufacturer's directions. The antisense riboprobes were synthesized by in vitro transcription (19) of p52PB linearized with HindIII using T7 RNA polymerase and incorporating [32P]UTP. Each hybridization included 10–100 ng of total cellular RNA and 5 × 10^5 cpn riboprobe with incubations for 18 h at 42°C. All riboprobes were present in >10-fold excess relative to the cellular 52-kD SS-A/Ro mRNA hybrids in the RNA preparations. RNase A was used at 250 U/ml and RNase T1 at 10,000 U/ml. The labeled probe hybridized to complementary mRNA in the sample mixture is “protected” from ribonuclease digestion, separated on 15% polyacrylamide gels, and visualized by autoradiography.

**In Vitro Transcription and Translation.** Since p52-2 represents a partial cDNA for 52B, an expression vector containing a full-length cDNA lacking exon 4 was constructed from p52FL following the protocol described in the site-directed mutagenesis kit (Transformer, CLONTECH). The primer 5'-AAGAGACGACGACTGGAAG|GAGGTGATAATTGTCCTG-3' was designed with the 5' half corresponding to the 3' end of exon 3 and the 3' half to the 5' end of exon 5. After initial priming with the mutant primer to generate deletion mutants, nonmutated plasmid was activated by digestion with SfiI restriction enzyme, which cut within exon 4 alone (see Fig. 1). After SfiI digestion, the mutated plasmid preparation was transformed into the Escherichia coli DH5α. A clone p52B was selected, and DNA sequencing was used to confirm the complete in-frame deletion of exon 4. For the synthesis of full-length 52B, plasmid p52B was linearized with HindIII and used as a substrate for in vitro transcription using T3 RNA polymerase and translation using a rabbit reticulocyte lysate (TNT Coupled Reticulocyte Lysate System; Promega, Madison, WI) in the presence of [35S]methionine (Trans-35S-label, 70% methionine and 15% cysteine, ICN Biochemicals, Inc., Costa Mesa, CA) as described (20). A second construct, which resulted in the deletion of the COOH-terminal 115 amino acid residues (equivalent to amino acids [aa] 360–475 of 52-kD SS-A/Ro), was obtained by digestion of p52B with the restriction enzyme PstI before in vitro transcription and translation.

**DNA Amplification Method.** First-strand synthesis was accomplished using 1 μg of poly(A)^+ RNA containing 40 U RNasin (Promega) in the 3' rapid amplification of cDNA ends (3' RACE) system ( Gibco BRL, Gaithersburg, MD) as described by the supplier. This cDNA was used for both 3' RACE and reverse transcription (RT)-PCR. PCR was performed using a cycler (TC9600; Perkin-Elmer, Oberlingen, Germany). The 50-μl reaction was performed in a 1× Taq buffer containing 2 U Taq polymerase (Gibco BRL), 2.5 mM MgCl2, 200 mM of each dNTP, 20 pmol of each primer, and 100 ng of cDNA. Amplification was started by heating for 2 min to 94°C. 30 cycles followed, each consisting of 1 min at 94°C, 2 min at 55°C, and 1.5 min at 72°C. The temperature was then held for 10 min at 72°C and cooled down to 4°C. 6 μl of the respective product was mixed with 1.5 μl of sample buffer (50% glycerol, 0.25% bromphenol blue in H2O) and applied to a 1.5–1.8% agarose gel in Tris-borate EDTA buffer for analysis. For determination of the molecular weights of the PCR products, 250 ng of ΘX174 DNA HaeIII digest (Gibco BRL) was run in parallel. The gels were subsequently stained with ethidium bromide, and photographs were taken (film 667; Polaroid Corp., Cambridge, MA).

3' RACE amplifications were performed for 30 cycles using a primer spanning bases 423–443 (5'-TATGTGCCCGACTCTCG-GAAAC-3') located upstream of the sequence encoding the leucine zipper of the 52-kD SS-A/Ro. Amplification products were purified (MicroSpin S-400 HR Columns; Pharmacia Biotech Inc., Piscataway, NJ). 2 μl of purified product was amplified by an additional 30 cycles using a nested primer covering bases 609–628 (5'-AATCTAGGATTCAGGAGGAGT-3'). Both amplifications were done in combination with the Universal Amplification Primer of the 3' RACE kit.

RT-PCR was performed using the same reaction conditions with the sense primer spanning bases 423–443 as used in 3' RACE, and an antisense primer covering bases 1377–1396 (5'-GGCAGATCCAGAGAAGGAGT-3'). After the first 30 cycles, the amplification products were run on a 1.5% Tris-acetate EDTA gel. The lower 0.78-kb band was purified and used as a template in a second round of amplification with the same primers. Selected amplification products were cloned using the TA cloning kit (Invitrogen, San Diego, CA) as described by the manufacturer, and DNA sequencing was used to confirm their identity.

**Patient Sera.** Sera from 32 women whose children had neonatal lupus (30 CHB, 2 cutaneous manifestations) were tested in immunoprecipitation of the in vitro–translated radiolabeled 52B form and the COOH-terminal truncated fragment (two mothers were only tested with the deletion mutant and one mother was only tested with the 52B form). Of these women, 8 had Sjögren’s syndrome (SS), 12 had SLE, 4 had an undifferentiated autoimmune syndrome (UAS), and 9 were completely asymptomatic. All sera were previously demonstrated to have antibodies to the 52-kD SS-A/Ro (defined by ELISA or SDS-immunoblot).

Patients classified as SLE met the criteria of the American College of Rheumatology (formerly, the American Rheumatism Association) (21). Six of the patients considered to have SS had symptomatic dry eyes and/or dry mouth, plus ophthalmological confirmation of keratoconjunctivitis sicca (22) and/or a positive salivary gland biopsy according to the recommendations of T. E. Daniels (23). One mother whose child had neonatal lupus was categorized as having SS but had dry eyes and mouth without objective criteria, and one mother, also best categorized as SS, had only parotid swelling as an adult, which required treatment with glucocorticoids. The sera from patients with SS and SLE were selected because they contained anti-52-kD SS-A/Ro reactivity and were from mothers whose children had neonatal lupus and thus do not represent a random sample of patients with SS and SLE. Patients were considered to have UAS if they had symptoms but did not meet criteria for the diagnosis of SLE, SS, or rheumatoid arthritis.

Of the 32 neonatal lupus sera tested, 26 (81%) had been previously evaluated in an analysis of antigenic regions of the 52-kD SS-A/Ro (20). 14 tested were previously known to react with *Staphylococcus aureus* V8 protease digestion fragments of the 52-kD SS-A/Ro, aa1–291, aa1–151, and aa1–78 (type II reactivity). 11 sera were previously known to react only with fragment aa1–291 and did not immunoprecipitate the more NH2-terminal fragments aa1–151 or aa1–78 (type I reactivity). One serum further evaluated in this study was marginally positive for anti-52-kD SS-A/Ro antibodies by ELISA but did not immunoprecipitate the radiolabeled protein. Six of the maternal sera had not been previously tested by immunoprecipitation or reported.

**Immunoprecipitation.** Immunoprecipitation of the in vitro translation products was performed as described (20). Briefly, 1 μl of patient’s serum was mixed with 50 μl 50% protein A Sepharose, 100 μl 10-mg/ml BSA, 200 μl reaction buffer (150 mM NaCl, 4 mM EDTA, 50 mM Tris-HCl, pH 7.4, 0.5% NP-
40, 0.5% sodium deoxycholate, and 0.1% SDS), and 1 μl of the labeled in vitro translation product. For evaluation of the deletion mutant, 10 μl of sera and 10 μl of the radiolabeled protein were used. The reaction mixtures, in 1.5-ml Eppendorf tubes, were rotated at 4°C for 1–3 h. The beads were then washed four times with chilled reaction buffer, eluted, boiled with reducing SDS sample buffer, and then run on 15% high-ratio monomer: cross-linker acrylamide gels overnight at 7.5 mA until the bromophenol blue dye front ran off (24). The gel was then stained with Coomassie blue dye and destained to visualize molecular weight markers and to ensure uniformity of immunoglobulin heavy and light chains precipitated in each reaction, dried with heat and vacuum, and placed with film at −70°C.

**Results**

52-kD cDNA Variant. During the screening of the MOLT-4 cell cDNA library to obtain the full-length cDNA for the 52-kD SS-A/Ro as described in our original report (5), clone p52-2 with a 1.4-kb insert was found also to be specific in the DNA hybridization reaction with the 52-kD cDNA probe. Initial DNA sequence determinations showed that the 5' end of p52-2 started at nucleotide position 257 (full-length cDNA 1.9 kb; reference 5), while the 3’ end matched perfectly those of other cDNAs for 52-kD SS-A/Ro. By comparison with the full-length cDNA, it was apparent that there might be an internal deletion of ~243 nucleotides [nt] (1.9 kb - 1.4 kb - 257nt = 243nt) in the p52-2 cDNA. As the complete nucleotide sequence was determined for p52-2, a deletion of 231nt was confirmed corresponding to a loss of 77 amino acid residues (aa168-245) spanning the leucine zipper region (Fig. 1). This deletion suggested that an alternative mRNA might be encoded in general, there is a major difference in the location of the promoter region would have been ~3 kb upstream of exon 2 in clone G33. To confirm that exon 1 is a functional exon and to determine the transcriptional start site, 5' RACE was used to obtain sequences upstream of the published noncoding sequence (5). Only one single band of 118 bp (including the sequence of the anchor primer) was identified in the right products (Fig. 1, second arrow), in one clone at position 2 (second arrow), and six clones at position 11 (third arrow). The sequence data are consistent with the agarose gel analysis above, which demonstrated a single band; thus, transcription begins in a relatively restricted region. The identification of exon 1 as delineated herein is significant, since in a recent report (25) the promoter region would have been located ~3 kb downstream in intron 1. Further analysis of the promoter activity for the 52-kD SS-A/Ro gene will be provided in a separate report.

---

**Figure 1.** Identification of an internal deletion in a MOLT-4 cell cDNA for the 52-kD SS-A/Ro. Compared with the sequence of the full-length cDNA p52FL, 231 bp (equivalent to 77 aa) were found to be absent in p52-2. Solid boxes represent the open-reading frame, and the numbers are the amino acid with respect to the full-length protein.

**Figure 2.** Human gene for the 52-kD SS-A/Ro protein. Two AFIXII clones, G5 and G33, initially selected by DNA hybridization, were found to be overlapping as shown schematically. The 52-kD SS-A/Ro gene spans 10 kb of DNA and is composed of seven exons. The translation initiation and stop codons are located in exon 2 and 7, respectively. The alternative form 52β is derived from splicing of exon 3 to exon 5, skipping exon 4 containing the coiled coil/leucine zipper domain. Repetitive sequence elements such as LINE, Alu elements, and simple repeats of the T and G nucleotides (TG repeat) are indicated as they are often found in introns.
The originally identified cDNA clone p52-2 can now be accounted for as a product of mRNA derived from splicing of exon 3 to exon 5, skipping exon 4 as shown in Fig. 2. The complete sequence corresponding to the 52-kD SS-A/Ro protein is 13,270nt, as shown in Fig. 3, and has been submitted to GenBank/EMBL under accession number U01882. The tissue expression of the 52[3 form (B). The intensity of the alternatively spliced form of the 52-kD SS-A/Ro protein in selected tissues as shown in Fig. 4. In the alternative 52[3 form, the first coiled coil is intact, whereas the second coiled coil, which includes the leucine zipper motif, is deleted. It is of note that the coiled coils predicted by the COILS program can be located in the aa sequence as heptad repeats (see Fig. 3).

**Figure 3.** Complete genomic sequence for the 52-kD SS-A/Ro protein. Only the relevant sequences are shown, but the complete sequence of 13,270nt including >4-kb upstream sequences derived from clone G23 has been submitted to GenBank/EMBL under accession number U01882. Upstream sequence, exons, and introns are indicated by upper case, bold-type upper case, and lower case nucleotide sequences, respectively. The region for transcriptional initiation is underlined, and the three arrows indicate the start sites most frequently detected in 5' RACE mapping. Translation start and stop codons are indicated by rectangles. Cysteine and histidine residues that are the backbone of the putative zinc fingers are indicated by inverted triangles. The key residues of the heptad repeat positions 1 or 7.

**Tissue Expression of the 52[3 Form.** Ribonuclease protection was the initial approach taken to identify the alternatively spliced form of the 52-kD SS-A/Ro protein in various human tissues. As seen in Fig. 5, the RNA probe generated from p52PB (covering 674-964) (A) hybridized to two protected fragments in a 24-wk fetal heart, one of 290nt corresponding to expression of the 52[3 form, and a smaller mRNA fragment of 144nt that likely represented a 52[3 form (B). The intensity of the alternatively spliced form increased in parallel with the quantity of RNA in the hybridization reaction. The expression of 52[3 was clearly observed with 80 μg of RNA (B, lane 4). There were no detectable bands when the RNA probes were hybridized to yeast RNA (data not shown). The two fragments were also detected in 17-, 19-, and 22-week fetal hearts, fetal liver and lung, and adult heart (data not shown).

RT-PCR was used to identify the mRNA for 52[3. First-strand synthesis was performed using mRNA from two 14-wk fetal hearts, three 16-wk fetal hearts, one 24-wk fetal heart, and adult heart. The resulting cDNA was amplified with a sense primer spanning bases 423-443 in the full-length 52-kD SS-A/Ro (upstream of region encoded by exon 4) and an antisense primer spanning bases 1377–1396. Two products were amplified in all tissues, one
A

| Exon | Size (bp) | 5' Splice donor | Intron | Size (bp) | 3' Splice acceptor |
|------|-----------|-----------------|--------|-----------|-------------------|
| 1    | 52        | GTAAAG          | 1      | 3173      | CAGAAG            |
| 2    | 457       | TACCAAG         | 2      | 2532      | GAAGAG            |
| 3    | 96        | TGAGAG          | 3      | 1123      | AAAACA            |
| 4    | 231       | CTGAGA          | 4      | 1306      | GAAGAG            |
| 5    | 23        | GAAAG           | 5      | 713       | GAGTGA            |
| 6    | 101       | GTGAGA          | 6      | 303       | TGCCAAG           |

Donor: AAG geaagt
Acceptor: cccccccccccag

B

Figure 4. 52β generated from alternative splicing. (A) Summary of exons, introns, and splicing sites for the 52-kD SS-A/Ro gene. With the exception of four nucleotides (bold type) at the 3' splice of intron 3, sequences for 5' and 3' splice sites are in strong agreement with known consensus sequences. (B) Prediction of coiled coils in 52-kD SS-A/Ro. The second coiled coil corresponding to exon 4 alone is absent in 52β.

Figure 5. RNase protection of 52-kD SS-A/Ro RNA. (A) Schematic diagram of RNA probe and predicted fragments corresponding to the 52α and β forms. (B) RNase protection of 10–80 μg RNA (lanes 1–4) from a 24-wk fetal heart probed with RNA spanning bases 674–964. In addition to the predominant protected fragment of 291nt corresponding to 52α detected in all four lanes, a 144nt fragment is seen in lanes 3 and 4. All RNA hybridizations were incubated with 50 U RNase A and 2,000 U RNase T1.
RT-PCR analysis of 52-kD SS-A/Ro mRNA. Using the sense primer spanning bases 423-443 and an antisense primer covering bases 1377-1936 of the known sequence for 52-kD SS-A/Ro, two fragments corresponding to the 52α and 52β were amplified from cDNA of a 16-wk fetal heart, 24-wk fetal heart, and adult heart. The 0.78-kb fragment in the 16-wk fetal heart was subcloned, and nucleotide sequencing confirmed that it represented 52β type mRNA.

Table 1. Immunoprecipitation of the 35S-radiolabeled 52β Form and COOH-terminal Truncated Fragment

| Disease   | 52β (aa1–398) | 52β (aa1–283) |
|-----------|---------------|---------------|
| SS (n = 8) |               |               |
| Type I    | 1 (1)         | 0 (1)         |
| Type II   | 3 (3)         | 4 (4)         |
| Not tested | 2 (2)         | 2 (2)         |
| No IP     | 0 (1)         | 0 (1)         |
| SLE (n = 11) |           |               |
| Type I    | 6 (6)         | 2 (6)         |
| Type II   | 2 (3)         | 3 (4)         |
| Not tested | 0 (1)         | 0 (1)         |
| UAS (n = 4) |             |               |
| Type I    | 0 (0)         | 0 (0)         |
| Type II   | 3 (3)         | 2 (3)         |
| Not tested | 1 (1)         | 0 (0)         |
| Asymptomatic (n = 9) |          |               |
| Type I    | 4 (4)         | 0 (4)         |
| Type II   | 3 (3)         | 3 (3)         |
| Not tested | 1 (2)         | 0 (2)         |
| Totals    | 26 (30) = 87% | 16 (31) = 52% |

All sera tested were from mothers whose children had manifestations of neonatal lupus. Type I sera (n = 11) recognized the central region of the 52-kD SS-A/Ro protein including the region encoded by exon 4. Type II sera (n = 14) recognized the central region as well as the NH2-terminal region aa1–78 as discussed in Materials and Methods and in reference 20. Six sera not previously tested in immunoprecipitation but which recognized recombinant 52-kD SS-A/Ro by ELISA or immunoblot of MOLT-4 are designated “not tested.” Serum from one patient with SS was weakly positive with the recombinant 52-kD SS-A by ELISA but was unreactive by immunoprecipitation, here noted as “no IP.” Two sera (one SS, one UAS) were only tested with the COOH deletion fragment. One sera (UAS) was only tested with the 52β form. Numbers represent those positive of the total number tested.

Figure 7. Representative immunoprecipitations of 35S-radiolabeled 52β SS-A/Ro and COOH-terminal truncated fragment by varied sera. (A) Immunoprecipitations with either the 52β form (lanes 1–10) or the truncated fragment (lanes 12–20) were performed as described in Materials and Methods. The sera used in lanes 1–10 are identical to those used in lanes 11–20, respectively. The clinical assignment is given above each lane: SS, ASYM (asymptomatic), or SLE. Control, two different sera selected from six healthy donors tested. The manifestations of the mother’s affected child, CHB or skin, are noted. (I), Type I reactivity; (II), type II reactivity; nt, not tested previously by immunoprecipitation. (B) Schematic representation of the 52α, 52β, and 52β deletion mutant. The sticky end, present in both the 52α and β forms, was previously defined as aa439–475 in 52α (20). The 52β mutant, in which the COOH terminus (aa360–475 of 52α) is deleted by digestion of p52β with the restriction enzyme PstI, does not contain the sticky end. As previously reported, type I anti-52 responses are characterized by recognition of the central region of 52α. Type II anti-52 responses are characterized by recognition of the central region of the 52α form as well as the NH2-terminal region (20).

As had been observed with immunoprecipitations of 52α (20, 29), minor background reactivity was noted with control sera (Fig. 7A, lanes 6–9, type I reactivity).

onstrated to recognize the 52β form by ELISA and/or immunoprecipitation also recognized the 52β form. 26 (87%) of 30 sera tested from mothers whose children were known to have neonatal lupus immunoprecipitated the 52β form. This result was unexpected. 11 of the 26 immunoprecipitating sera were previously shown to be reactive with aa1–291 and not aa1–78 or 1–151, implying that in these sera the epitope recognized was within a region on the 52α form encoded by exon 4 and absent in the 52β form (Fig. 7A, lanes 6–9, type I reactivity).

As had been observed with immunoprecipitations of 52α (20, 29), minor background reactivity was noted with control sera (Fig. 7A, lanes 1 and 5) that increased in parallel with the quantity of sera used. Our earlier experiments
demonstrated that a “sticky” region of the 52α form mapped to aa439–475 (20). Therefore, sera from the affected mothers were also tested for reactivity with a PstI restriction digest of the 52β form in which the COOH-terminal 115aa were deleted (Fig. 7 B). As expected, sera that had previously been shown to react with both the central region of the 52α form as well as the NH2 terminus immunoprecipitated this PstI digest (Fig. 7 A, lanes 12–14). Specifically, 12 (86%) of the 14 type II responders immunoprecipitated the 52β deletion fragment (the two unreactive sera were the weakest type II responders previously identified). In contrast, of 11 antisera that were reactive solely with the central region, only 2 (18%) were reactive with the deletion fragment, and both were substantially weaker than the reactivity observed with the type II sera. A summary of the reactivity segregated by disease and previously defined epitope specificity is provided in Table 1. Immunoreactivity with the 52β form suggests that antigenicity of the 52-kD SS-A/Ro protein is not dependent on the putative leucine zipper domain.

Discussion

The 52-kD SS-A/Ro protein is expressed in a variety of human cells and tissues and, because of its sequence motifs, is likely to have an important function in transcriptional activity. An antibody response to the 52-kD SS-A/Ro protein has been nearly universally demonstrated either by immunoprecipitation, ELISA, or immunoblot in mothers whose children have manifestations of neonatal lupus (1–4). Isolation of a cDNA clone encoding the 52-kD SS-A/Ro protein was accomplished using the sera from one of these mothers. The molecular characterization of the 52-kD SS-A/Ro protein is now extended by further analysis of the complete genomic structure and the description of an alternative transcript.

In addition to the cDNA clones originally reported (5), an interesting MOLT-4 cDNA clone 52-2 was found to have an internal deletion of 231 nt including the domain encoding the leucine zipper motif. The calculated masses for the full-length 52-kD SS-A/Ro (52α) and the alternative form (52β) are 54,000 and 45,000, respectively. To investigate the nature of the deletion found in clone 52-2, a full-length human 52-kD SS-A/Ro cDNA was used to isolate clones from a λFIXII genomic library. The 52-kD SS-A/Ro gene is comprised of seven exons and covers 10 kb of DNA. The alternative form of the 52-kD mRNA results from splicing of exon 3 to exon 5, skipping exon 4. DNA sequencing unambiguously demonstrates mRNA expression of the 52β form in the human fetal heart. Data obtained with RNase protection assay and PCR suggest that this form is present in other tissues, including the adult heart.

The identification of an alternatively spliced form of the 52-kD SS-A/Ro that lacks a potentially functional domain common to DNA binding proteins, nuclear transforming proteins, and transcriptional regulatory proteins is of potential biologic interest. The internal deletion of aa168–245, which includes the leucine zipper, may affect protein–protein interaction and subsequent DNA binding, molecular functions ascribed to proteins with this putative motif (30). Since the 52β form includes the NH2-terminal zinc finger domains, it would be expected to retain the same DNA/RNA-binding function as that predicted for the 52α form. Accordingly, the 52β form could function as a competitive inhibitor of the 52-kD SS-A/Ro protein, since both would compete for the same putative DNA/RNA-binding site.

Although there is no direct evidence that the newly described 52β form is important in the pathogenesis of neonatal lupus, several requisite conditions for its potential involvement have been met. First, a 52β form mRNA transcript is expressed in the fetal heart, particularly during the window of presumed vulnerability, 16–24 wk of gestational age (31). Further analysis will reveal whether there is overexpression of this alternative form relative to the full-length form in fetal versus adult heart tissue. Second, the β form is translated, at least in an in vitro system, and is antigenic, immunoprecipitated by >80% of numerous sera from mothers whose children have neonatal lupus.

It is of particular interest that the majority of mothers whose children have neonatal lupus react with this novel 52β form, since in previous studies (20) approximately half of these antisera were found to react only with the central region of the 52α form, deleted in the β form. As demonstrated with the full-length 52α form, there was background stickiness noted with normal human sera, which complicates the interpretation of true reactivity (20, 29). However, reactivity with sera from affected mothers was clearly greater than that observed with controls. These observations suggest that exposure of a novel epitope may have occurred by altered folding of the protein due to deletion of the central coiled coil region.

To completely eliminate the background stickiness previously attributed to aa439–475 of the full-length 52-kD SS-A/Ro protein, a truncated form of 52β in which the terminal 115aa were deleted was used in immunoprecipitation. As expected, all but two antisera that previously demonstrated reactivity with the NH2-terminal region of the full-length 52α form immunoprecipitated this 52β COOH-terminal deletion mutant. In contrast, only rare sera that were apparently dependent on the central region of the 52α form for reactivity immunoprecipitated the 52β mutant. These data support several conclusions. Exposure of a novel immunodominant epitope in the 52β form may be dependent on the COOH terminus. The NH2-terminal region spanning the zinc finger domains constitutes a restricted epitope in both 52 isoforms. The 52-kD SS-A/Ro protein can certainly be recognized in the absence of the putative leucine zipper domain or adjacent NH2-terminal amino acid residues 197–207, a region previously reported to be required for recognition by antisera from 21 patients with SLE (32).

At the present time, there is no definitive proof of in vivo translation of the 52β protein from this newly described alternative transcript. However, the mRNA is efficiently translated in a rabbit reticulocyte system. The eval-
ulation of protein expression on SDS-immunoblot is complicated, since reactivity with the 48-kD SS-B/La and its 43-kD degradation product might obscure reactivity with the newly described 52β form, predicted to be 45 kD. To eliminate any confusion with SS-B/La, several sera devoid of 48-kD SS-B/La antibodies as measured by ELISA were evaluated on SDS-immunoblot. Intriguingly, these sera did not recognize any bands below the 52-kD protein (data not shown). This observation suggests that, unlike the 52α form, reactivity with the 52β form may be dependent on native structure as reported for the 60-kD SS-A/Ro protein (33, 34). Nevertheless, on immunoblot of transfected Hep-2 cells overexpressing the 52β form, rabbit anti-52-kD SS-A/Ro sera clearly reacted with a band at 45 kD not detected in untransfected cells (data not shown). We have not attempted labeling of cells with 35S, since difficulty with this method has been noted for the 52α form as it has a long half-life relative to most of the common autoantigens (20).

An additional finding of this study was that the 52-kD SS-A/Ro (α form) expressed in the fetal heart was identical to that previously published in other tissues. The entire sequence for the full-length 52-kD SSA/Ro protein is highly homologous to the rfp protein, a cellular homologue of a human transforming protein, ret (7). The latter is a fusion protein comprised of the NH2-terminal zinc finger domain of rfp and a COOH-terminal domain deriving from a tyrosine kinase (28). The protein rfp is expressed in a variety of tumor cells and embryonic tissues. Inasmuch as the ret fusion protein has been shown to be a surface membrane protein, one plausible mechanism for the zinc finger of the 52-kD SSA/Ro protein to be expressed on the cell surface might be a DNA recombination event between the 52-kD protein gene and a tyrosine kinase gene as it did in the case of the ret oncogene. Our strategy was to clone flanking 3' regions that might be derived from such a putative gene fusion using 3' RACE, which generates cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' end. Accessibility of the putative 52α form in the fetal heart to maternal autoantibodies is as yet not explained by tissue-specific sequences.

In summary, a novel isoform of the 52-kD SS-A/Ro protein is described in which the central leucine zipper motif representing one of the two coiled coils has been deleted. In vitro-translated protein is recognized by antisera that also recognize the full-length 52α form, notably the majority of mothers whose children have manifestations of neonatal lupus. Further work will be needed to examine the expression of these two forms in affected hearts when they are available to determine the relative importance of 52α or 52β in the putative relationship of anti-52-kD autoantibodies to CHB. It is anticipated that the alternatively spliced form will provide insight into the function of the 52-kD SS-A/Ro and its intermolecular relationship to the 60-kD SS-A/Ro. In turn, this should facilitate a better understanding of the immune response to the SS-A/Ro autoantigens and its role in the development of neonatal lupus.

We acknowledge the assistance of Ms. Xiaoqing Guo and Ms. Ei-Hua Liang in DNA sequencing. Dr. Eng M. Tan is acknowledged for support and encouragement throughout this study.

This work was supported by the National Institutes of Health (NIH) grants AR-41803 and AR-42455 and the Systemic Lupus Erythematosus Foundation, Inc., New York. This work was also supported in part by the Sam and Rose Stein Charitable Trust and by the NIH grant M01RR00833 provided to the General Clinical Research Center of the Scripps Clinic and Research Foundation. This is publication 9192-MEM from The Scripps Research Institute.

Address correspondence to Jill P. Buyon, M.D., Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003.

Received for publication 6 March 1995 and in revised form 10 May 1995.

References
1. Buyon, J.P., R.J. Winchester, S.G. Slade, F. Arnett, J. Copel, D. Friedman, and M.D. Lockshin. 1993. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Arthritis & Rheum. 36:1263-1273.
2. Meilof, J.F., I.M.E. Frohn-Mulder, P.A. Stewart, A. Sztatman, J. Hess, C.H.A. Venhoven, R.J.T. Smeenk, and A.J.G. Swaak. 1993. Maternal autoantibodies and congenital heart block: no evidence for the existence of a unique heart block-associated anti-Ro/SS-A autoantibody profile. Lupus. 2:239-246.
3. Julkunen, H., P. Kurki, R. Kaaja, R. Heikkila, L. Ilykka, E.K.L. Chan, E. Wallgren, and C. Friman. 1993. Isolated congenital heart block: long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis & Rheum. 36:1588-1598.
4. Lee, L.A., M.B. Frank, V.R. McCubbin, and M. Reichlin. 1994. Autoantibodies of neonatal lupus erythematosus. J. Invest. Dermatol. 102:963-966.
5. Chan, E.K.L., J.C. Hamel, J.P. Buyon, and E.M. Tan. 1991.
Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J. Clin. Invest. 87: 68–76.

Itoh, K., Y. Itoh, and M.B. Frank. 1991. Protein heterogeneity in the human Ro/SSA ribonucleoproteins. J. Clin. Invest. 87:177–186.

Takahashi, M., Y. Inaguma, H. Hiai, and F. Hirose. 1988. Developmentally regulated expression of a human “finger”-containing gene encoded by the 5’ half of the ret transforming gene. Mol. Cell. Biol. 8:1853–1856.

Patarca, R., G.J. Freeman, J. Schwartz, R.P. Singh, Q.T. Kong, E. Murphy, Y. Anderson, F.Y. Sheng, P. Singh, K.A. Johnson, et al. 1988. rpt-1, an intracellular protein from helper/inducer T cells that regulates gene expression of interleukin 2 receptor and human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 85:2733–2737.

Miki, Y., J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L.M. Bennett, W. Ding, et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Wash. DC). 266:66–71.

Frank, M.B., K. Itoh, A. Fujisaku, P. Pontarotti, M.G. Mattei, and B.R. Neas. 1993. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms. Am. J. Hum. Genet. 52:183–191.

Kozak, M. 1991. An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol. 115:887–903.

Troster, H., T.E. Metzger, I.M. Sensei, M. Schwemmle, A. Winerpacht, B. Zabel, and M.B. Bachmann. 1994. One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjögren’s syndrome. J. Exp. Med. 180:2059–2067.

Ben-Chetrit, E., B.J. Gandy, E.M. Tan, and K.F. Sullivan. 1989. Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J. Clin. Invest. 83:1284–1292.

Deutscher, S.L., J.B. Harley, and J.D. Keene. 1982. Molecular analysis of the 60kDa human Ro ribonucleoprotein. Proc. Natl. Acad. Sci. USA. 85:9479–9483.

Bingham, P.M., T.B. Chou, I. Mims, and Z. Zachar. 1988. On/off regulation of gene expression at the level of splicing. Trends Genet. 4:134–138.

Feinberg, A.P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6–13.

Hirzmann, J.D., D. Luo, J. Hahnen, and G. Hobom. 1993. Determination of messenger RNA 3’-ends by reverse transcription of the cap structure. Nucleic Acids Res. 19:3597–3598.

Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156–159.

Krieg, P.A., and D.A. Melton. 1987. In vitro RNA synthesis with SP6 RNA polymerase. Methods Enzymol. 155:397–415.

Buyon, J.P., S.G. Slade, J.D. Reveille, J.C. Hamel, and E.K.L. Chan. 1994. Autoantibody responses to the “native” 52kD SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus and Sjögren’s syndrome. J. Immunol. 152:3675–3684.

Tan, E.M., A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, J.G. Schaller, N. Talal, and R.J. Winchester. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheum. 25:1271–1277.

Fox, R.I., C.A. Robinson, J.G. Curd, F. Kozin, and F.V. Howell. 1986. Sjögren syndrome: proposed criteria for classification. Arthritis & Rheum. 29:577–585.

Daniels, T.E. 1984. Labial salivary gland biopsy in Sjögren’s syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis & Rheum. 27:147–156.

Buyon, J.P., S.G. Slade, E.K.L. Chan, E.M. Tan, and R. Winchester. 1990. Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. J. Immunol. Methods. 129:207–210.

Tsug, H., R.M. Horowitz, N. Gibson, and M.B. Frank. 1994. The location of a disease associated polymorphism and genomic structure of the human 52-kDa Ro/SSA locus (SSA1). Genomics. 24:541–548.

Shapiro, M.B., and P. Senapathy. 1987. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res. 15:7156–7174.

Lupas, A., M. Van Dyke, and J. Stock. 1991. Predicting coiled coils from protein sequences. Science (Wash. DC). 252:1162–1164.

Tangnichi, M., T. Iwamoto, M. Hamaguchi, M. Matsuyama, and M. Takahashi. 1991. The ret oncogene products are membrane-bound glycoproteins phosphorylated on tyrosine residues in vivo. Biochem. Biophys. Res. Commun. 181:416–422.

Bozic, B., G.J.M. Pruijfin, B. Rozman, and W.J. van Venrooj. 1993. Sera from patients with rheumatic diseases recognize different epitope regions on the 52-kD Ro/SS-A protein. Clin. Exp. Immunol. 94:227–235.

Landschulz, W.H., P.F. Johnson, and S.L. McKnight. 1988. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science (Wash. DC). 240:1759–1764.

Waltuck, J., and J.P. Buyon. 1994. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann. Intern. Med. 120:544–551.

Frank, M.B., K. Itoh, and V. McCubbin. 1994. Epitope mapping of the 52kD Ro/SSA autoantigen. Clin. Exp. Immunol. 95:390–396.

Boire, G., F.J. Lopez-Longo, S. Lapointe, and H.A. Menard. 1993. Sera from patients with autoimmune disease recognize conformational determinants on the 60-kD Ro/SS-A protein. Arthritis & Rheum. 34:722–730.

Reichlin, M., and Y. Itoh. 1991. The autoimmune response to the Ro/SSA antigen is conformation dependent. In Arthritis and Rheumatism Council for Research Conference Proceedings, No. 8. Fetal and Neonatal Effects Associated with Maternal Rheumatic Diseases: An Insight into Disease Mechanisms. P.V. Taylor and J.S. Scott, editors. The Arthritis and Rheumatism Council, Derbyshire, UK. 37–41.